Avaliação do SUVmax na captação do [68Ga]Ga-DOTA-TATE PET/CT em doentes com tumores neuroendócrinos: revisão de literatura

Autores

  • Carolina Maricato Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa. Lisboa, Portugal.
  • Isabel Aguiar Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa. Lisboa, Portugal.
  • Susana Valente Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa. Lisboa, Portugal. Unidade de Medicina Nuclear, Hospital Lusíadas. Lisboa, Portugal.
  • Sérgio Figueiredo H&TRC – Health & Technology Research Center, Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa. Lisboa, Portugal.

Palavras-chave:

SUVmax, [68Ga]Ga-DOTA-TATE, PET/CT, NET

Resumo

Introdução – O cálculo do maximum standardized uptake value (SUVmax) em tomografia por emissão de positrões (PET) com [68Ga]Ga-DOTA-TATE permite quantificar a densidade de recetores da somatostatina, sobreexpressos  pelos tumores neuroendócrinos (TNE). A sua análise em função do padrão normal e patológico complementa a avaliação visual dos exames, mas na literatura existe controvérsia quanto a esta diferenciação. O objetivo deste trabalho foi avaliar os valores de SUVmax fisiológico (SUVmax_f) e patológico (SUVmax_p) em função da captação de [68Ga]Ga-DOTA-TATE em diferentes órgãos. Materiais e Métodos – Esta revisão sistemática foi conduzida de acordo com as orientações da checklist Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). A pesquisa incluiu os termos relacionados com SUVmax, PET/CT, [68Ga]Ga-DOTA-TATE e NET, na PubMed, Scopus e Web of Science. Os estudos selecionados foram referentes a TNE avaliados por PET/CT com [68Ga]Ga-DOTA-TATE, com discriminação da localização, dos valores de  SUVmax e do grau histológico das lesões. Utilizaram-se técnicas de estatística descritiva para análise dos dados. Resultados/Discussão – Dos 20 artigos selecionados obtiveram-se valores de SUVmax_f e SUVmax_p de vários órgãos. Os gânglios linfáticos, a hipófise, o pâncreas e o fígado foram os órgãos que apresentaram a maior diferença entre os valores de SUVmax_f e SUVmax_p, respetivamente: (1,1) e (6,0; 26,3), (2,0; 11,0) e (24,2), (3,5; 9,2) e (20,4; 87,6), e (6,5; 10,1) e (14,5; 40,0). O reduzido número de amostras e a inclusão de lesões de diferentes graus histológicos parece ter influenciado esta segmentação. Conclusão – O valor médio de SUVmax_f e SUVmax_p do [68Ga]Ga-DOTA-TATE é variável nos diferentes órgãos. A avaliação deste parâmetro permite estabelecer a distinção entre captação fisiológica e patológica, particularmente em órgãos como gânglios linfáticos, pâncreas, hipófise e trato gastrointestinal (GI).  

Referências

Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19(12):991-1002.

Chauhan A, Yu Q, Ray N, Farooqui Z, Huang B, Durbin EB, et al. Global burden of neuroendocrine tumors and changing incidence in Kentucky. Oncotarget. 2018;9(27):19245-54.

Yalcin S, Aberg K, editors. Neuroendocrine tumours: diagnosis and management [Internet]. Berlin: Springer; 2015. Available from: http://link.springer.com/10.1007/978-3-662-45215-8

Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707-12.

Öberg K, Sundin A. Imaging of neuroendocrine tumors. In: Front Horm Res. 2016;45:142-51.

Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res. 1994;54(13):3455-9.

Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30(5):781-93.

Miękus N, Bączek T. Non-invasive screening for neuroendocrine tumors: biogenic amines as neoplasm biomarkers and the potential improvement of 'gold standards'. J Pharm Biomed Anal. 2016;130:194-201.

Aluri V, Dillon JS. Biochemical testing in neuroendocrine tumors. Endocrinol Metab Clin North Am. 2017;46(3):669-77.

Maxwell JE, Howe JR. Imaging in neuroendocrine tumors: an update for the clinician. Int J Endocr Oncol. 2015;2(2):159-68.

Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. Eur J Nucl Med Mol Imaging. 2017;44(9):1588-601.

Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35(8):1431-8.

Kunikowska J, Królicki L, Pawlak D, Zerizer I, Mikołajczak R. Semiquantitative analysis and characterization of physiological biodistribution of 68Ga-DOTA-TATE PET/CT. Clin Nucl Med. 2012;37(11):1052-7.

Bodei L, Ambrosini V, Herrmann K, Modlin I. Current concepts in68Ga-DOTATATE imaging of neuroendocrine neoplasms: interpretation, biodistribution, dosimetry, and molecular strategies. J Nucl Med. 2017;58(11):1718-26.

Yu J, Li N, Li J, Lu M, Leal JP, Tan H, et al. The correlation between [68Ga]DOTATATE PET/CT and cell proliferation in patients with GEP-NENs. Mol Imaging Biol. 2019;21(5):984-90.

Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, et al. Comparison of 68 Ga-DOTANOC and 68 Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54(3):364-72.

Hogg P, Testanera G, editors. Principles and practice of PET/CT - Part 1: a technologist’s guide. Vienna: European Association of Nuclear Medicine; 2010.

Brendle C, Kupferschläger J, Nikolaou K, La Fougère C, Gatidis S, Pfannenberg C. Is the standard uptake value (SUV) appropriate for quantification in clinical PET imaging? Variability induced by different SUV measurements and varying reconstruction methods. Eur J Radiol. 2015;84(1):158-62.

Lodge MA, Chaudhry MA, Wahl RL. Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med. 2012;53(7):1041-7.

Kunikowska J, Pawlak D, Kolasa A, Mikoałajczak R, Królicki L. A frequency and semiquantitative analysis of pathological 68Ga DOTATATE PET/CT uptake by primary site-dependent neuroendocrine tumor metastasis. Clin Nucl Med. 2014;39(10):855-61.

Kuyumcu S, Özkan ZG, Sanli Y, Yilmaz E, Mudun A, Adalet I, et al. Physiological and tumoral uptake of 68Ga-DOTATATE: standardized uptake values and challenges in interpretation. Ann Nucl Med. 2013;27(6):538-45.

Haug AR, Rominger A, Mustafa M, Auernhammer C, Göke B, Schmidt GP, et al. Treatment with octreotide does not reduce tumor uptake of 68 Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med. 2011;52(11):1679-83.

Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, et al. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39(8):1271-7.

Haug AR, Auernhammer CJ, Wängler B, Schmidt GP, Uebleis C, Göke B, et al. 68 Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51(9):1349-56.

Wang H, Cheng Y, Zhang J, Zang J, Li H, Liu Q, et al. Response to single low-dose 177 Lu-DOTA-EB-TATE treatment in patients with advanced neuroendocrine neoplasm: a prospective pilot study. Theranostics. 2018;8(12):3308-16.

Aalbersberg EA, de Wit-van der Veen BJ, Versleijen MW, Saveur LJ, Valk GD, Tesselaar ME, et al. Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation. Eur J Nucl Med Mol Imaging. 2019;46(3):696-703.

Ingenerf M, Kiesl S, Karim S, Beyer L, Ilhan H, Rübenthaler J, et al. 68Ga-DOTATATE PET/CT and MRI with diffusion-weighted imaging (DWI) in short-and long-term assessment of tumor response of neuroendocrine liver metastases (NELM) following transarterial radioembolization (TARE). Cancers (Basel). 2021;13(17):4321.

Teker F, Elboga U. Is SUVmax a useful marker for progression-free survival in patients with metastatic GEP-NET receiving 177Lu-DOTATATE therapy? Hell J Nucl Med. 2021;24(2):122-31.

Rodrigues M, Thorstensen E, Uprimny C, Kendler D, Virgolini I, Warwitz B. Intraindividual comparison of SUVmax, SUVmean and tumor volume results with Lu-177-DOTA-TATE SPECT/CT and Ga-68-DOTA-TOC PET/CT in neuroendocrine tumor patients. Eur J Nucl Med Mol Imaging. 2016;43(1):S326.

Zheng Y, Wang H, Tan H, Cui X, Yao S, Zang J, et al. Evaluation of lung cancer and neuroendocrine neoplasm in a single scan by targeting both somatostatin receptor and integrin αvβ3. Clin Nucl Med. 2019;44(9):687-94.

Ilhan H, Lindner S, Todica A, Cyran CC, Tiling R, Auernhammer CJ, et al. Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2020;47(4):870-80.

Lindner S, Simmet M, Gildehaus FJ, Jurkschat K, Wängler C, Wängler B, et al. Automated production of [18F]SiTATE on a scintomics GRPTM platform for PET/CT imaging of neuroendocrine tumors. Nucl Med Biol. 2020;88-89:86-95.

Loft M, Carlsen EA, Johnbeck CB, Johannesen HH, Binderup T, Pfeifer A, et al. 64Cu-DOTATATE PET in patients with neuroendocrine neoplasms: prospective, head-to-head comparison of imaging at 1 hour and 3 hours after injection. J Nucl Med. 2021;62(1):62-8.

Niedermoser S, Chin J, Wängler C, Kostikov A, Bernard-Gauthier V, Vogler N, et al. In vivo evaluation of 18 F-SiFA lin –modified TATE: a potential challenge for 68 Ga-DOTATATE, the clinical gold standard for somatostatin receptor imaging with PET. J Nucl Med. 2015;56(7):1100-5.

Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, et al. Quantitative and qualitative intrapatient comparison of 68 Ga-DOTATOC and 68 Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med. 2014;55(2):204-10.

Haug AR, Assmann G, Rist C, Tiling R, Schmidt GP, Bartenstein P, et al. Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using 68Ga-DOTATATE PET/CT. Radiologe. 2010;50(4):349-54.

Ilan E, Sandström M, Velikyan I, Sundin A, Eriksson B, Lubberink M. Parametric net influx rate images of 68Ga-DOTATOC and 68Ga-DOTATATE: quantitative accuracy and improved image contrast. J Nucl Med. 2017;58(5):744-9.

Atkinson C, Ganeshan B, Endozo R, Wan S, Aldridge MD, Groves AM, et al. Radiomics-based texture analysis of 68Ga-DOTATATE positron emission tomography and computed tomography images as a prognostic biomarker in adults with neuroendocrine cancers treated with 177Lu-DOTATATE. Front Oncol. 2021;11:686235.

Xie Q, Liu T, Ding J, Zhou N, Meng X, Zhu H, et al. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2021;48(10):3129-40.

Lakhotia R, Jhawar S, Malayeri AA, Millo C, Del Rivero J, Ahlman MA. Incidental 68Ga-DOTATATE uptake in the pancreatic head. Medicine. 2020;99(22):e20197.

Liu KY, Goldrich DY, Ninan SJ, Filimonov A, Lam H, Govindaraj S, et al. The value of 68Gallium-DOTATATE PET/CT in sinonasal neuroendocrine tumor management: a case series. Head Neck. 2021;43(6):E30-40.

van Zanten SE, Bos EM, Verburg FA, van Doormaal PJ. Intracranial hemangiopericytoma showing excellent uptake on arterial injection of [68Ga]DOTATATE. Eur J Nucl Med Mol Imaging. 2021;48(5):1673-4.

Ambinder EB, Werner RA, Rowe SP. Incidental primary breast cancer detected on surveillance 68Ga-DOTATATE PET/CT in a patient with metastatic neuroendocrine carcinoma. Radiol Case Rep. 2020;15(8):1344-7.

Papadakis GZ, Millo C, Sadowski SM, Karantanas AH, Bagci U, Patronas NJ. Fibrous dysplasia mimicking malignancy on 68Ga-DOTATATE PET/CT. Clin Nucl Med. 2017;42(3):209-10.

Tolomeo A, Lopopolo G, Dimiccoli V, Perioli L, Modoni S, Scilimati A. Impact of 68Ga-DOTATOC PET/CT in comparison to 111In-octreotide SPECT/CT in management of neuro-endocrine tumors. Medicine. 2020;99(7):e19162.

Tuzcu SA, Pekkolay Z. Multiple endocrine neoplasia type 2A syndrome (MEN2A) and usefulness of 68Ga-DOTATATE PET/CT in this syndrome. Ann Ital Chir. 2019;90:497-503.

Panagiotidis E, Alshammari A, Michopoulou S, Skoura E, Naik K, Maragkoudakis E, et al. Comparison of the impact of 68 Ga-DOTATATE and 18 F-FDG PET/CT on clinical management in patients with neuroendocrine tumors. J Nucl Med. 2017;58(1):91-6.

Sampathirao N, Basu S. MIB-1 index–stratified assessment of dual-tracer PET/CT with 68 Ga-DOTATATE and 18 F-FDG and multimodality anatomic imaging in metastatic neuroendocrine tumors of unknown primary in a PRRT workup setting. J Nucl Med Technol. 2017;45(1):34-41.

You H, Sanli Y, Subramaniam RM. Impact of point-spread function reconstruction on 68Ga-DOTATATE PET/CT quantitative imaging parameters. AJR Am J Roentgenol. 2019;213(3):683-8.

Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, et al. Prospective study of 68 Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol. 2016;34(6):588-96.

Kaemmerer D, Wirtz RM, Fischer EK, Hommann M, Sänger J, Prasad V, et al. Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET/CT Data in patients with pancreatic neuroendocrine neoplasm. Pancreas. 2015;44(4):648-54.

Liu Q, Cheng Y, Zang J, Sui H, Wang H, Jacobson O, et al. Dose escalation of an Evans blue–modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2020;47(4):947-57.

Karls S, Gold R, Kravets S, Wang Y, Cheng SC, Perez K, et al. Correlation of 68Ga-DOTATATE uptake on PET/CT with pathologic features of cellular proliferation in neuroendocrine neoplasms. Ann Nucl Med. 2021;35(9):1066-77.

Parghane RV, Bhandare M, Chaudhari V, Ostwal V, Ramaswamy A, Talole S, et al. Surgical feasibility, determinants, and overall efficacy of neoadjuvant 177 Lu-DOTATATE PRRT for locally advanced unresectable gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2021;62(11):1558-63.

Menon BK, Kalshetty A, Bhattacharjee A, Basu S. Standardized uptake values and ratios on 68Ga-DOTATATE PET-computed tomography for normal organs and malignant lesions and their correlation with Krenning score in patients with metastatic neuroendocrine tumors. Nucl Med Commun. 2020;41(10):1095-9.

Cox CP, Segbers M, Graven LH, Brabander T, van Assema DM. Standardized image quality for 68Ga-DOTA-TATE PET/CT. EJNMMI Res. 2020;10(1):27.

Zhang J, Liu Q, Singh A, Schuchardt C, Kulkarni HR, Baum RP. Prognostic value of 18F-FDG PET/CT in a large cohort of patients with advanced metastatic neuroendocrine neoplasms treated with peptide receptor radionuclide therapy. J Nucl Med. 2020;61(11):1560-9.

Parghane RV, Naik C, Talole S, Desmukh A, Chaukar D, Banerjee S, et al. Clinical utility of 177Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity. Head Neck. 2020;42(3):401-16.

Ilan E, Velikyan I, Sandström M, Sundin A, Lubberink M. Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using 68Ga-DOTATOC and 68Ga-DOTATATE. J Nucl Med. 2020;61(2):217-21.

Liu Q, Zang J, Yang Y, Ling Q, Wu H, Wang P, et al. Head-to-head comparison of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in localizing tumors with ectopic adrenocorticotropic hormone secretion: a prospective study. Eur J Nucl Med Mol Imaging. 2021;48(13):4386-95.

Hou J, Long T, He Z, Zhou M, Yang N, Chen D, et al. Evaluation of 18F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: comparison with 68Ga-DOTATATE PET/CT. EJNMMI Res. 2021;11(1):55.

Sanchez S, Currie GM. Topical sensor for the assessment of PET dose administration: metric performance with an autoinjector. J Nucl Med Technol. 2020;48(4):363-71.

Ragab A, Wu J, Ding X, Clark A, Mischen B, Chauhan A, et al. 68Ga-DOTATATE PET/CT: the optimum standardized uptake value (SUV) internal reference. Acad Radiol. 2022;29(1):95-106.

Cleary JO, Yeung J, McMeekin H, Wilhelm T, Wagner T. The significance of incidental brain uptake on 68Ga-DOTATATE PET-CT in neuroendocrine tumour patients. Nucl Med Commun. 2016;37(11):1197-205.

Gofrit ON, Frank S, Meirovitz A, Nechushtan H, Orevi M. PET/CT with 68Ga-DOTA-TATE for diagnosis of neuroendocrine: differentiation in patients with castrate-resistant prostate cancer. Clin Nucl Med. 2017;42(1):1-6.

Demirci E, Ocak M, Kabasakal L, Araman A, Ozsoy Y, Kanmaz B. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results. Nucl Med Commun. 2013;34(8):727-32.

Seystahl K, Stoecklein V, Schüller U, Rushing E, Nicolas G, Schäfer N, et al. Somatostatin-receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68 Ga-DOTATATE/-TOC uptake. Neuro Oncol. 2016;18(11):1538-47.

Has Simsek D, Isik EG, Engin MN, Kuyumcu S, Mudun A, Sanli Y. Somatostatin receptor-positive breast lesions on 68Ga-DOTATATE PET/CT. Ann Nucl Med. 2021;35(2):270-7.

Lou R, Lazor JW, Baraban E, Ware JB, Cooper K, Pantel AR. 68Ga-DOTATATE uptake in an endolymphatic sac tumor: radiologic-pathologic correlation. Clin Nucl Med. 2020;45(7):563-5.

Daniel KB, Santos AO, Andrade RA, Trentin MB, Garmes HM. Evaluation of 68Ga-DOTATATE uptake at the pituitary region and the biochemical response to somatostatin analogs in acromegaly. J Endocrinol Invest. 2021;44(10):2195-202.

Guirguis MS, Adrada BE, Surasi DS, Dryden MJ. 68Ga-DOTATATE uptake in primary breast cancer. Clin Nucl Med. 2021;46(3):248-9.

Kohlenberg JD, Panda A, Johnson GB, Castro MR. Radiologic and clinicopathologic characteristics of thyroid nodules with focal 68Ga-DOTATATE PET activity. Nucl Med Commun. 2021;42(5):510-6.

Thakur S, Daley B, Millo C, Cochran C, Jacobson O, Lu H, et al. 177Lu-DOTA-EB-TATE, a radiolabeled analogue of somatostatin receptor type 2, for the imaging and treatment of thyroid cancer. Clin Cancer Res. 2021;27(5):1399-409.

Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, et al. A comparison of 68 Ga-DOTATATE and 18 F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med. 2009;50(12):1927-32.

Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112(11):2447-55.

Ayati N, Lee ST, Zakavi R, Pathmaraj K, Al-Qatawna L, Poon A, et al. Long-acting somatostatin analog therapy differentially alters 68 Ga-DOTATATE uptake in normal tissues compared with primary tumors and metastatic lesions. J Nucl Med. 2018;59(2):223-7.

Novruzov F, Aliyev A, Wan MYS, Syed R, Mehdi E, Aliyeva I, et al. The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors. Eur J Hybrid Imaging. 2021;5(1):10.

Liberini V, Kotasidis F, Treyer V, Messerli M, Orita E, Engel-Bicik I, et al. Impact of PET data driven respiratory motion correction and BSREM reconstruction of 68Ga-DOTATATE PET/CT for differentiating neuroendocrine tumors (NET) and intrapancreatic accessory spleens (IPAS). Sci Rep. 2021;11(1):2273.

Mapelli P, Tam HH, Sharma R, Aboagye EO, Al-Nahhas A. Frequency and significance of physiological versus pathological uptake of 68Ga-DOTATATE in the pancreas. Nucl Med Commun. 2014;35(6):613-9.

Moradi F, Minamimoto R, Jamali M, Barkhodari A, Quon A, Mittra E, et al. Physiological distribution of 68Ga-DOTA-TATE: an atlas of standardized uptake values. J Nucl Med. 2015;56(Suppl 3):1285.

Fendler WP, Barrio M, Spick C, Allen-Auerbach M, Ambrosini V, Benz M, et al. 68 Ga-DOTATATE PET/CT interobserver agreement for neuroendocrine tumor assessment: results of a prospective study on 50 patients. J Nucl Med. 2017;58(2):307-11.

Lastoria S, Marciello F, Faggiano A, Aloj L, Caracò C, Aurilio M, et al. Role of 68Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1). Endocrine. 2016;52(3):488-94.

Sainz-Esteban A, Prasad V, Schuchardt C, Zachert C, Carril JM, Baum RP. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39(3):501-11.

Ocak M, Demirci E, Kabasakal L, Aygun A, Tutar RO, Araman A, et al. Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer. Nucl Med Commun. 2013;34(11):1084-9.

Baratto L, Toriihara A, Hatami N, Aparici CM, Davidzon G, Levin CS, et al. Results of a prospective trial to compare68ga-dota-tate with sipm-based pet/ct vs. conventional PET/CT in patients with neuroendocrine tumors. Diagnostics. 2021;11(6):992.

Tuncel M, Kılıçkap S, Süslü N. Clinical impact of 68Ga-DOTATATE PET-CT imaging in patients with medullary thyroid cancer. Ann Nucl Med. 2020;34(9):663-74.

Ladwa R, Pattison D, Smith J, Goodman S, Burg M, Rose S, et al. Pretherapeutic predictors of tumor absorbed dosimetry in radionuclide therapy for metastatic neuroendocrine tumors. Neuroendocrinology. 2018;106:250.

Ladwa R, Pattison D, Smith J, Goodman S, Burge M, Rose S, et al. Positron emission tomography (PET) predictors of tumor response to peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors (NET). Neuroendocrinology. 2018;106:249.

Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, et al. 68 Ga-DOTATOC Versus 68 Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52(12):1864-70.

Lee H, Eads JR, Pryma DA. 68Ga‐DOTATATE positron emission tomography‐computed tomography quantification predicts response to somatostatin analog therapy in gastroenteropancreatic neuroendocrine tumors. Oncologist. 2021;26(1):21-9.

Özgüven S, Filizoğlu N, Kesim S, Öksüzoğlu K, Şen F, Öneş T, et al. Physiological biodistribution of 68Ga-Dota-Tate in normal subjects. Mol Imaging Radionucl Ther. 2021;30(1):39-46.

Xia Y, Zeng C, Zhao Y, Zhang X, Li Z, Chen Y. Comparative evaluation of 68Ga-labelled TATEs: the impact of chelators on imaging. EJNMMI Res. 2020;10(1):36.

Zhu W, Cheng Y, Wang X, Yao S, Bai C, Zhao H, et al. Head-to-head comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in patients with metastatic, well-differentiated neuroendocrine tumors: a prospective study. J Nucl Med. 2020;61(6):897-903.

Zhang P, Yu J, Li J, Shen L, Li N, Zhu H, et al. Clinical and prognostic value of PET/CT imaging with combination of 68 Ga-DOTATATE and 18 F-FDG in gastroenteropancreatic neuroendocrine neoplasms. Contrast Media Mol Imaging. 2018;2018:2340389.

Abdulrezzak U, Kurt YK, Kula M, Tutus A. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors. Nucl Med Commun. 2016;37(8):874-81.

Alonso O, Rodríguez-Taroco M, Savio E, Bentancourt C, Gambini JP, Engler H. 68Ga-DOTATATE PET/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin. Ann Nucl Med. 2014;28(7):638-45.

Simsek DH, Kuyumcu S, Turkmen C, Sanlı Y, Aykan F, Unal S, et al. Can complementary 68 Ga-DOTATATE and 18 F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? J Nucl Med. 2014;55(11):1811-7.

Shastry M, Kayani I, Wild D, Caplin M, Visvikis D, Gacinovic S, et al. Distribution pattern of 68Ga-DOTATATE in disease-free patients. Nucl Med Commun. 2010;31(12):1025-32.

Brogsitter C, Zöphel K, Hartmann H, Schottelius M, Wester H-J, Kotzerke J. Twins in spirit part II: DOTATATE and high-affinity DOTATATE—the clinical experience. Eur J Nucl Med Mol Imaging. 2014;41(6):1158-65.

Moradi F, Jamali M, Barkhodari A, Schneider B, Chin F, Quon A, et al. Spectrum of 68Ga-DOTA TATE uptake in patients with neuroendocrine tumors. Clin Nucl Med. 2016;41(6):e281-7.

Coura-Filho GB, Hoff AA, Duarte PS, Buchpiguel CA, Josefsson A, Hobbs RF, et al. 68Ga-DOTATATE PET: temporal variation of maximum standardized uptake value in normal tissues and neuroendocrine tumours. Nucl Med Commun. 2019;40(9):920-6.

Reubi JC, Waser B, Horisberger U, Krenning E, Lamberts SW, Gebbers JO, et al. In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. Blood. 1993;82(7):2143-51.

Boy C, Heusner TA, Poeppel TD, Redmann-Bischofs A, Unger N, Jentzen W, et al. 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1–sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging. 2011;38(7):1224-36.

Jindal T, Kumar A, Venkitaraman B, Meena M, Kumar R, Malhotra A, et al. Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids. Cancer Imaging. 2011;11(1):70-5.

Haug A, Auernhammer CJ, Wängler B, Tiling R, Schmidt G, Göke B, et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2009;36(5):765-70.

Hoberück S, Michler E, Zöphel K, Platzek I, Kotzerke J, Brogsitter C. Brain metastases of a neuroendocrine tumor visualized by 68Ga-DOTATATE PET/CT. Clin Nucl Med. 2019;44(1):50-2.

Popovic B, Macut D, Petakov M, Bozic I, Bogavac T, Isailovic T, et al. Adrenal lesions in patients with neuroendocrine tumors. Endocr Abstr. 2013;32:P535.

Chang CA, Pattison DA, Tothill RW, Kong G, Akhurst TJ, Hicks RJ, et al. 68Ga-DOTATATE and 18F-FDG PET/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging. 2016;16(1):22.

Maclean J, Aldridge M, Bomanji J, Short S, Fersht N. Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation. Pituitary. 2014;17(6):530-8.

Zhao X, Xiao J, Xing B, Wang R, Zhu Z, Li F. Comparison of 68Ga DOTATATE to 18F-FDG uptake is useful in the differentiation of residual or recurrent pituitary adenoma from the remaining pituitary tissue after transphenoidal adenomectomy. Clin Nucl Med. 2014;39(7):605-8.

Tjörnstrand A, Casar‐Borota O, Heurling K, Schöll M, Gjertsson P, Himmelman J, et al. Lower 68 Ga‐DOTATOC uptake in nonfunctioning pituitary neuroendocrine tumours compared to normal pituitary gland: a proof‐of‐concept study. Clin Endocrino. 2020;92(3):222-31.

Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, et al. Neuroendocrine hepatic metastases. Ann Surg. 2005;241(5):776-85.

Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50(Suppl 1):11S-20S.

Westerterp M, Pruim J, Oyen W, Hoekstra O, Paans A, Visser E, et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging. 2007;34(3):392-404.

Subramaniam RM, Bradshaw ML, Lewis K, Pinho D, Shah C, Walker RC. ACR Practice parameter for the performance of gallium-68 DOTATATE PET/CT for neuroendocrine tumors. Clin Nucl Med. 2018;43(12):899-908.

Downloads

Publicado

13-03-2023

Como Citar

Maricato, C., Aguiar, I., Valente, S., & Figueiredo, S. (2023). Avaliação do SUVmax na captação do [68Ga]Ga-DOTA-TATE PET/CT em doentes com tumores neuroendócrinos: revisão de literatura. Saúde & Tecnologia. Obtido de https://journals.ipl.pt/stecnologia/article/view/747

Edição

Secção

Artigos de Revisão